Top 10 Blue Chip Stocks To Own Right Now

May 23, 2017: Markets opened higher again Tuesday but have not moved much higher as the session went on. The blue chips performed best with particular strength in financials. Tech stocks and consumer discretionaries are on track for a down finish. WTI crude oil for July delivery settled at $51.47 a barrel, up 0.7%. June gold dipped 0.5% for the day to settle at $1,255.60. Equities were headed for a mixed close shortly before the bell as the DJIA traded up 0.16% for the day, the S&P 500 traded up 0.14%, and the Nasdaq Composite traded down 0.01%.

The DJIA stock posting the largest daily percentage gain ahead of the close Tuesday was The Goldman Sachs Group Inc. (NYSE: GS) which traded up 1.75% at $219.80. The stock’s 52-week range is $138.20 to $3255.15. Volume was about 30% below the daily average of around 3.7 million shares. The company had no specific news Monday.

JPMorgan Chase & Co. (NYSE: JPM) traded up 1.28% at $85.78. The stock’s 52-week range is $57.05 to $93.98. Volume was about 40% below the daily average of around 14.8 million shares. The big bank had no specific news.

Top 10 Blue Chip Stocks To Own Right Now: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap insurance software stock Ebix Inc (NASDAQ: EBIX) reported Q1 2017 earnings before the market opened this morning. Q1 revenue rose 11% to $79.1 million and decreased 1% over Q4 2016 revenue of $80.0 million. The year over year revenue improvement reflected growth in the Companys Exchange, Risk Compliance, and Broker Solution channels. On a constant currency basis, Q1 revenue increased 10% to $78.5 millionwith theExchange channel continued to bethe Companyslargest -accounting for 67% of Q1 2017 revenues. Q1 2017 net income rose 19% to $26.4 million with the improvement principally reflected the benefit of higher revenues and operating income as compared to the same period last year.

Top 10 Blue Chip Stocks To Own Right Now: 21Vianet Group, Inc.(VNET)

Advisors’ Opinion:

  • [By Leo Sun]

    In a previous article, I reviewed why GoPro, Twilio, and Wuba.com were all cut in half in 2016. Today I’ll add two Chinese tech stocks to that list — Renren (NYSE:RENN) and 21Vianet (NASDAQ:VNET) — which both lost more than half their value over the past 12 months.

  • [By Monica Gerson]

    21Vianet Group Inc (NASDAQ: VNET) shares rose 5.88 percent to $15.30 in the pre-market trading session as the company reported a $388 million investment by TUS Holdings.

Top 10 Blue Chip Stocks To Own Right Now: The Charles Schwab Corporation(SCHW)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Vanguard's latest fee cuts answer two such moves this year, including one this month, by rival BlackRock, Inc. (NYSE: BLK) and one fee reduction announcement by Charles Schwab Corp (NYSE: SCHW).

  • [By Garrett Baldwin]

    The ongoing trade rift between the United States and China continues to plague international markets. Despite reports that both countries are working behind the scenes to prevent additional detrimental trade policies, both countries recently proposed tens of billions in new tariffs on one another. The United States has accused China of widespread intellectual property theft, while China has accused the United States of unfair trade practices, including price manipulation in the agricultural industry. This morning, it’s worth noting that proposed tariffs on U.S. business jets will likely not provide a competitive advantage to foreign competition. Reuters reports that Chinese aviation executives do not see the layer of protectionism as a way to bolster the nation’s local market. Check back to Money Morning today for more insight on how the ongoing trade war could affect your investments.
    Finally, investors will continue to monitor ongoing developments in Washington around the presidency of Donald Trump. The White House has asked a federal judge to block prosecutors from reviewing any files seized from his lawyer’s office during a raid by the FBI last week. The agency seized a trove of documents from lawyer Michael Cohen’s office as part of an investigation into a payment of hush money. The spat between the White House and the FBI continues a day after former FBI Director James Comey called Trump “morally unfit to be president.”
    Three Stocks to Watch Today: BAC, NFLX, AAPL
    Shares of Bank of America Corp. (NYSE: BAC) added nearly 1% after the nation’s largest bank by deposits topped Wall Street earning expectations. The financial institution leads a busy day of earnings reports on Wall Street and hopes to keep its positive momentum from previous quarters. The firm reported earnings per share of $0.62 on top of $23.27 billion in revenue. That topped expectations of $0.59 on top of $22.91 billion thanks to strong growth in its consumer loan business and the r

  • [By Lee Jackson]

    Charles Schwab Corp. (NYSE: SCHW) also had a famous investor selling stock this past week. The chairman of the company, Charles Schwab, continues to sell stock at an orderly pace. This week the iconic discount brokerage executive and the CEO of the company combined to sell a block of 400,000 shares at prices between $35.43 and $35.46. The total for the trades came to a whopping $14 million.As we have noted in the past, Mr. Schwab is past 80 years old, and clearly much of his selling over the years has been for estate planning purposes. The shares endedFriday at $37.48 so a fair amount left on the table.

  • [By Lee Jackson]

    Charles Schwab Corp. (NYSE: SCHW) had a famous investor selling stock this past week. Chairman Charles Schwab continues to sell stock at an orderly pace. This week the iconic discount brokerage executive sold 600,000 shares at prices between $32.50 and $33.75. The total for the trade came to a whopping $20 million.As we have noted in the past, Schwab is past 80 years old and clearly much of his selling over the years has been for estate planning purposes. The shares traded Friday at $35.25, so a fair amount left on the table.

  • [By Tyler Crowe, Tim Brugger, and Jordan Wathen]

    With that in mind, we asked three of our contributors to highlight a company they will be following closely in the first quarter and why. Here’s what makes Adobe Systems (NASDAQ:ADBE), Charles Schwab (NYSE:SCHW), and U.S. Silica Holdings (NYSE:SLCA) worth following when the next earnings report comes out.

  • [By ]

    Darn hard to not like the numbers out of Action Alerts PLUS holding JPMorgan & Chase (JPM) . Profits up nicely in all segments vs. the fourth quarter. Big year-over-year spikes in return on assets and equity from a year ago. Trading revenue up thanks to the return of volatility in the first quarter (can’t wait to see the blowout quarters from TD Ameritrade (AMTD) and Schwab (SCHW) ). Good card revenue growth from the fourth-quarter bodes well for retailer’s first-quarter results.

Top 10 Blue Chip Stocks To Own Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Peter Graham]

    On the other hand, small cap wearables stock Biotricity (OTCQB: BTCY)is a different wearables play as theCompanys mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricitys R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The Company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

Top 10 Blue Chip Stocks To Own Right Now: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

Top 10 Blue Chip Stocks To Own Right Now: Coca-Cola Bottling Co. Consolidated(COKE)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Coca-Cola Bottling Co. (NYSE: COKE) had a revenue increase to $2.3 billion in its most recentfiscal year, from $1.7 billion in the previous one. It is moving into Ohio, Indiana, Kentucky, Illinois and West Virginia, which almost certainly will require capital. Its net sales rose 37% in the most recent quarter to $840 million. Management stated this was because of “Organic growth in the legacy territories as well as territory expansion through the acquisition of several new distribution territories from Coca-Cola led to the solid performance.” The current dividend is $1, or 0.66%.

Top 10 Blue Chip Stocks To Own Right Now: Glaukos Corporation(GKOS)

Advisors’ Opinion:

  • [By Nelson Hem]

    In "Skeptics Eye Potential Trouble for Glaukos," Vito J. Racanelli suggests that, even though Glaukos Corp (NYSE: GKOS) has warned that it might lose money this year, Wall Street appears to be betting otherwise. This eye-stent maker has had success with a breakthrough product and dominates its market, but formidable competition still looms.

Top 10 Blue Chip Stocks To Own Right Now: Zillow Group, Inc.(ZG)

Advisors’ Opinion:

  • [By Steve Symington]

    The stock market was mostly flat today ahead of a key House vote on the passage of the Republicans’ healthcare bill, which was delayed until Friday after GOP lawmakers failed to gather the necessary support. TheDow Jones Industrial Averagelost just 5 points, or 0.02%, while other broader market indexes saw similar small declines. But several individual stocks saw much more severe drops, including Zillow Group (NASDAQ:Z) (NASDAQ:ZG), Proofpoint (NASDAQ:PFPT), and Accenture (NYSE:ACN). Read on to see what drove these unusual moves.

  • [By Steve Symington]

    Shares of Zillow Group Inc. (NASDAQ:Z)(NASDAQ:ZG)climbed 13.8% in the month of April,according to data provided byS&P Global Market Intelligence, ahead of the online real estate specialist’s impending first-quarter 2017 report.

Top 10 Blue Chip Stocks To Own Right Now: Varex Imaging Corporation (VREX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Varex Imaging (VREX), a stock that wasn’t even in the index yesterday, soared to the top of the S&P 500 today after being spun out of Varian Medical Systems (VAR).

    Agence France-Presse/Getty Images

    Varex Imaging gained 7.3% to $27.27 today, while the S&P 500 declined 0.6% to2,280.90. Varian Medical Systems fell 1.2% to $77.68.

    Varian Medical Systems reported net income of $402 million on sales of $3.2 billion in 2016.

  • [By Jim Robertson]

    Small cap homeland security and screening stocks like FLIR Systems (NASDAQ: FLIR), OSI Systems (NASDAQ: OSIS),Varex Imaging Corp (NASDAQ: VREX) and Patriot One Technologies (OTCQB: PTOTF) stand to benefit fromTrumps focus on border andinternal security in general. Heres what you need to know about all four:

Top 10 Blue Chip Stocks To Own Right Now: Nordstrom Inc.(JWN)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    The mall was created by accident, in some ways. Downtown Bloomington, Minnesota, lost its two largest corporate residents in 1982, football’s Minnesota Vikings and baseball’s Minnesota Twins. Over 78 acres became available for development. After debates about what should happen to the land, local officials decided to give it to financiers who wanted to build America’s largest home for retailers. It opened in 1992, two years before Amazon.com Inc. (NASDAQ: AMZN) was founded. Early tenants included Macy’s Inc. (NYSE: M), the Sears division of Sears Holdings Corp. (NASDAQ: SHLD) and Nordstrom Inc. (NYSE: JWN). All three have been injured by the current downturn in traditional retail sales.

  • [By ]

    Some reasons for my bearishness on retail stocks:

    Higher Energy Prices. Oil prices have rallied dramatically and back to 2014 levels, rising from about $35 a barrel in early 2016 to around $67 Thursday. That’s bad news for U.S. retailers, as rising oil prices historically squeeze consumer disposable incomes. That’s one reason why I’ve been consistently raising my short exposure to retail and plan to continue doing so. Shaky Same-Store Sales Growth. Recent improvements to same-store sales at Abercrombie & Fitch (ANF) , Urban Outfitters (URBN) , Dillard’s (DDS) , Gap Inc. (GPS) and Macy’s (M) come against downgraded expectations, and might not be sustainable anyway. No Deal for Nordstrom (JWN) . The Nordstrom family has apparently abandoned plans to take its namesake company private. I had expressed concerns that this would happen. Higher Interest Rates. A rise in the London Inter-Bank Offered Rate (LIBOR) has recently accelerated. That’s bad news for retailers, as many variable-rate consumer debts (particularly mortgages) key off of the LIBOR. This will likely put a damper on mortgage refinancings — something that many see as an important ingredient for personal-consumption expenditures.

  • [By Rich Duprey]

    An increasing number of retailers have announced their intention to drop Ivanka Trump’s merchandise line. From Nordstrom (NYSE:JWN) and Belk to Neiman-Marcus and Burlington, there’s a growing movement for retailers to distance themselves from the Trump brand.

  • [By Chris Lange]

    Look for Nordstrom Inc. (NYSE: JWN) to reveal its fiscal second-quarter results on Thursday as well. The consensus analyst estimates are $0.63 in EPS and revenue of $3.74 billion. Shares of Nordstrom closed at $46.81 on Friday, above the consensus price target of $46.00. The 52-week range is $39.53 to $62.82.